China-based biotechnology company Ascletis has closed a RMB 220m ($35m) series B round led by venture capital fund C-Bridge Capital that included drug developer Tasly Pharmaceutical and Pavilion Capital.
Founded in 2011, Ascletis is working on treatments for hepatitis C. The company successfully completed a Phase 2 clinical trial in Taiwan earlier this year and has filed an application with regulator China Food and Drug Administration to launch a Phase 2 trial in China.
Ascletis also has a treatment for…
